NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/04/2024
Voltar para busca
Dado oficial do USPTO
CELLIPONT BIOSERVICES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CELLIPONT BIOSERVICES
ST13
US500000097251361Classe
40, 42, 45
Pedido
97251361
Registro
7375156
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
30/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
40, 42, 45
Data de depósito
03/02/2022
Data de registro
30/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/04/2024
Última transação
30/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
14/02/2022
Primeiro uso no comércio
14/02/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Poway, CA, US
Examinador
O'BRIEN, JENNIFER
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Performance Cell Manufacturing, Inc.
Representantes
Paul J. Kennedy TROUTMAN PEPPER HAMILTON SANDERS LLP
Classificação técnica
Classes Nice
Classe 40Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Manufacturing services for others in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticalscustom manufacture of pharmaceuticalschemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing services for others in the fields of mammalian cell banksplasmidspurified mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalianscustom manufacture of pharmaceuticalschemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing process consulting; Production in the nature of custom manufacture of cell lines for others using lentivirus technology; Production in the nature of custom manufacture of a recombinant or manipulated lentivirus; Production in the nature of custom manufacture of mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalians
Classe 42
Research and development in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; scientific research and technical research servicesresearch and development in the fields of assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting servicesresearch and development in the fields of assayingpurifying mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalians; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for otherscGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management servicesquality evaluation and analysisquality assurancequality controlin the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; CDMO (Contract Development and Manufacturing Organization) servicespharmaceutical drug development services; material testing; product quality testing; scientific laboratory services; scientific research
Classe 45
Providing regulatory compliance and regulatory compliance consultation and advisory services with respect to relevant state and federal law for organizations in the pharmaceuticalbiotechlife scienceother government-regulated industries
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
30/04/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
29/03/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
28/03/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/03/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/03/2024
IUAF
USE AMENDMENT FILED
12/02/2024
EISU
TEAS STATEMENT OF USE RECEIVED
12/02/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
29/08/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/07/2023
PUBO
PUBLISHED FOR OPPOSITION
04/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/05/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/11/2022
GNRT
NON-FINAL ACTION E-MAILED
28/11/2022
CNRT
NON-FINAL ACTION WRITTEN
28/11/2022
DOCK
ASSIGNED TO EXAMINER
16/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/02/2022
NWAP
NEW APPLICATION ENTERED
07/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLIPONT BIOSERVICES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.